Related Experiment Video
Updated: Jul 7, 2026

Hippocampal Neuronal Cultures to Detect and Study New Pathogenic Antibodies Involved in Autoimmune Encephalitis
Published on: June 2, 2022
Cerebrospinal fluid 14-3-3-gamma protein level in eight HIV-negative cryptococcal meningitis adults
1Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan. cwenneng@ms19.hinet.net
Abstract:
The clinical data and cerebrospinal fluid (CSF) 14-3-3-gamma protein detection of eight adult HIV-negative cryptococcal meningitis (CM) cases were examined. The eight cases included six males and two females aged 35-70 years (mean = 49.8 years). The duration between the onset of CM symptoms and the first CSF study ranged from 1 to 60 days. Initial neuroimaging study was abnormal in 87.5% (7/8) of the cases. All the eight had positive initial and subsequent follow-up CSF 14-3-3-gamma protein detection. The densitometric values of CSF 14-3-3-gamma protein were not correlated with either the CSF white blood cell counts or the therapeutic results. The therapeutic results showed that three cases died and five survived. Significant neurologic deficits were shown in 60% (3/5) of the survivors. This study revealed that HIV-negative CM patients have elevated CSF 14-3-3-gamma protein levels, and that this level is not changed with a short-term treatment.
Insights
Elevated cerebrospinal fluid (CSF) 14-3-3-gamma protein is found in HIV-negative patients with cryptococcal meningitis (CM). This protein level did not change with short-term treatment in this study.
Area of Science:
- Neurology
- Infectious Diseases
- Biochemistry
Background:
- Cryptococcal meningitis (CM) is a serious fungal infection affecting the central nervous system.
- Diagnosis and prognosis in HIV-negative CM patients can be challenging.
- Cerebrospinal fluid (CSF) biomarkers are crucial for understanding CM pathogenesis and outcomes.
Purpose of the Study:
- To investigate the levels of CSF 14-3-3-gamma protein in adult HIV-negative patients with CM.
- To assess the correlation of CSF 14-3-3-gamma protein levels with clinical parameters and treatment outcomes.
- To determine if CSF 14-3-3-gamma protein levels change with short-term treatment.
Main Methods:
- Retrospective analysis of clinical data from eight adult HIV-negative CM cases.
- Detection and quantification of 14-3-3-gamma protein in cerebrospinal fluid (CSF) using specific assays.
- Correlation analysis between CSF 14-3-3-gamma protein levels, CSF white blood cell counts, and therapeutic results.
Main Results:
- All eight HIV-negative CM patients exhibited positive CSF 14-3-3-gamma protein detection at initial and follow-up studies.
- Elevated CSF 14-3-3-gamma protein levels were observed in this cohort.
- No significant correlation was found between CSF 14-3-3-gamma protein densitometric values and CSF white blood cell counts or therapeutic outcomes.
- Mortality rate was 37.5% (3/8), and 60% (3/5) of survivors experienced significant neurological deficits.
- CSF 14-3-3-gamma protein levels remained unchanged with short-term treatment.
Conclusions:
- HIV-negative CM patients demonstrate elevated CSF 14-3-3-gamma protein.
- CSF 14-3-3-gamma protein levels do not appear to correlate with disease severity markers or treatment response in the short term.
- Further research is warranted to explore the diagnostic and prognostic value of CSF 14-3-3-gamma protein in cryptococcal meningitis.
Related Concept Videos
Cryptococcal Meningitis
Viral Meningitis
Cerebrospinal Fluid
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain.
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Bacterial Meningitis I: Introduction

